DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples

Abstract Background The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with antiphospholipid syndrome (APS), a common...

Full description

Bibliographic Details
Main Authors: Steven Andrew Baker, Jing Jin, Christopher Pfaffroth, Trang Vu, James L. Zehnder
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
antibodies
antiphospholipid
antiphospholipid syndrome
apixaban
lupus coagulation inhibitor
partial thromboplastin time
Online Access:https://doi.org/10.1002/rth2.12472

Internet

https://doi.org/10.1002/rth2.12472

Similar Items